Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

C. L. Bennett, R. M. Golub, Elizabeth Calhoun, J. Weinstein, D. Fishman, J. Lurain, P. Roland, F. Medio, R. M. Bukowski

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Nearly 27,000 female patients were diagnosed with ovarian cancer in the United States in 1997. While chemotherapeutic agents are effective in prolonging the time to progression of disease, concerns exist over treatment- related toxicities. In addition to considerations related to effectiveness, the decision to prescribe new cytoprotective agents requires consideration of costs and cost-effectiveness. The objective of this study was to describe cost-utility estimates of a new supportive care agent, amifostine, and to illustrate these issues for patients with ovarian cancer. The phase III Food and Drug Administration (FDA) licensing trial found that pretreatment with amifostine prior to each cycle of chemotherapy resulted in reduction of cumulative toxicities with cyclophosphamide and cisplatinum. While amifostine use is approximately $3,146 more per patient, after adjustment for direct medical costs and potential health status changes from reductions in hematologic toxicity, neurotoxicity, and nephrotoxicity, its use was estimated to cost $36,161 in direct medical costs per quality-adjusted life year saved. Sensitivity analyses indicated that cost-effectiveness estimates of amifostine therapy ranged from $25,474 to $78,574. Based on the phase III FDA licensing trial, amifostine use is associated with a favorable cost- utility profile that is in the range associated with widely used cancer therapeutic and supportive care agents. The decision to use (or not use) amifostine in conjunction with cisplatin and cyclophosphamide for women with ovarian cancer should be based on clinical, not economic, considerations.

Original languageEnglish (US)
Pages (from-to)64-72
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume8
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Amifostine
Ovarian Neoplasms
Costs and Cost Analysis
United States Food and Drug Administration
Licensure
Cyclophosphamide
Cost-Benefit Analysis
Therapeutics
Quality-Adjusted Life Years
Cisplatin
Health Status
Disease Progression
Economics
Drug Therapy

Keywords

  • Amifostine
  • Cytoprotection
  • Ovarian cancer
  • Utility assessment

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Bennett, C. L., Golub, R. M., Calhoun, E., Weinstein, J., Fishman, D., Lurain, J., ... Bukowski, R. M. (1998). Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. International Journal of Gynecological Cancer, 8(1), 64-72.

Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. / Bennett, C. L.; Golub, R. M.; Calhoun, Elizabeth; Weinstein, J.; Fishman, D.; Lurain, J.; Roland, P.; Medio, F.; Bukowski, R. M.

In: International Journal of Gynecological Cancer, Vol. 8, No. 1, 1998, p. 64-72.

Research output: Contribution to journalArticle

Bennett, CL, Golub, RM, Calhoun, E, Weinstein, J, Fishman, D, Lurain, J, Roland, P, Medio, F & Bukowski, RM 1998, 'Cost-utility assessment of amifostine as first-line therapy for ovarian cancer', International Journal of Gynecological Cancer, vol. 8, no. 1, pp. 64-72.
Bennett, C. L. ; Golub, R. M. ; Calhoun, Elizabeth ; Weinstein, J. ; Fishman, D. ; Lurain, J. ; Roland, P. ; Medio, F. ; Bukowski, R. M. / Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. In: International Journal of Gynecological Cancer. 1998 ; Vol. 8, No. 1. pp. 64-72.
@article{0be95fc97b434798b7eae90733ed76e5,
title = "Cost-utility assessment of amifostine as first-line therapy for ovarian cancer",
abstract = "Nearly 27,000 female patients were diagnosed with ovarian cancer in the United States in 1997. While chemotherapeutic agents are effective in prolonging the time to progression of disease, concerns exist over treatment- related toxicities. In addition to considerations related to effectiveness, the decision to prescribe new cytoprotective agents requires consideration of costs and cost-effectiveness. The objective of this study was to describe cost-utility estimates of a new supportive care agent, amifostine, and to illustrate these issues for patients with ovarian cancer. The phase III Food and Drug Administration (FDA) licensing trial found that pretreatment with amifostine prior to each cycle of chemotherapy resulted in reduction of cumulative toxicities with cyclophosphamide and cisplatinum. While amifostine use is approximately $3,146 more per patient, after adjustment for direct medical costs and potential health status changes from reductions in hematologic toxicity, neurotoxicity, and nephrotoxicity, its use was estimated to cost $36,161 in direct medical costs per quality-adjusted life year saved. Sensitivity analyses indicated that cost-effectiveness estimates of amifostine therapy ranged from $25,474 to $78,574. Based on the phase III FDA licensing trial, amifostine use is associated with a favorable cost- utility profile that is in the range associated with widely used cancer therapeutic and supportive care agents. The decision to use (or not use) amifostine in conjunction with cisplatin and cyclophosphamide for women with ovarian cancer should be based on clinical, not economic, considerations.",
keywords = "Amifostine, Cytoprotection, Ovarian cancer, Utility assessment",
author = "Bennett, {C. L.} and Golub, {R. M.} and Elizabeth Calhoun and J. Weinstein and D. Fishman and J. Lurain and P. Roland and F. Medio and Bukowski, {R. M.}",
year = "1998",
language = "English (US)",
volume = "8",
pages = "64--72",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

AU - Bennett, C. L.

AU - Golub, R. M.

AU - Calhoun, Elizabeth

AU - Weinstein, J.

AU - Fishman, D.

AU - Lurain, J.

AU - Roland, P.

AU - Medio, F.

AU - Bukowski, R. M.

PY - 1998

Y1 - 1998

N2 - Nearly 27,000 female patients were diagnosed with ovarian cancer in the United States in 1997. While chemotherapeutic agents are effective in prolonging the time to progression of disease, concerns exist over treatment- related toxicities. In addition to considerations related to effectiveness, the decision to prescribe new cytoprotective agents requires consideration of costs and cost-effectiveness. The objective of this study was to describe cost-utility estimates of a new supportive care agent, amifostine, and to illustrate these issues for patients with ovarian cancer. The phase III Food and Drug Administration (FDA) licensing trial found that pretreatment with amifostine prior to each cycle of chemotherapy resulted in reduction of cumulative toxicities with cyclophosphamide and cisplatinum. While amifostine use is approximately $3,146 more per patient, after adjustment for direct medical costs and potential health status changes from reductions in hematologic toxicity, neurotoxicity, and nephrotoxicity, its use was estimated to cost $36,161 in direct medical costs per quality-adjusted life year saved. Sensitivity analyses indicated that cost-effectiveness estimates of amifostine therapy ranged from $25,474 to $78,574. Based on the phase III FDA licensing trial, amifostine use is associated with a favorable cost- utility profile that is in the range associated with widely used cancer therapeutic and supportive care agents. The decision to use (or not use) amifostine in conjunction with cisplatin and cyclophosphamide for women with ovarian cancer should be based on clinical, not economic, considerations.

AB - Nearly 27,000 female patients were diagnosed with ovarian cancer in the United States in 1997. While chemotherapeutic agents are effective in prolonging the time to progression of disease, concerns exist over treatment- related toxicities. In addition to considerations related to effectiveness, the decision to prescribe new cytoprotective agents requires consideration of costs and cost-effectiveness. The objective of this study was to describe cost-utility estimates of a new supportive care agent, amifostine, and to illustrate these issues for patients with ovarian cancer. The phase III Food and Drug Administration (FDA) licensing trial found that pretreatment with amifostine prior to each cycle of chemotherapy resulted in reduction of cumulative toxicities with cyclophosphamide and cisplatinum. While amifostine use is approximately $3,146 more per patient, after adjustment for direct medical costs and potential health status changes from reductions in hematologic toxicity, neurotoxicity, and nephrotoxicity, its use was estimated to cost $36,161 in direct medical costs per quality-adjusted life year saved. Sensitivity analyses indicated that cost-effectiveness estimates of amifostine therapy ranged from $25,474 to $78,574. Based on the phase III FDA licensing trial, amifostine use is associated with a favorable cost- utility profile that is in the range associated with widely used cancer therapeutic and supportive care agents. The decision to use (or not use) amifostine in conjunction with cisplatin and cyclophosphamide for women with ovarian cancer should be based on clinical, not economic, considerations.

KW - Amifostine

KW - Cytoprotection

KW - Ovarian cancer

KW - Utility assessment

UR - http://www.scopus.com/inward/record.url?scp=0031886899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031886899&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 64

EP - 72

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -